L3VLUP
ProSign in

WST · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WSTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WST
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterWSTVRTX
Q3 202020 holders, $3.8bn31 holders, $21.9bn
Q4 202018 holders, $3.9bn30 holders, $18.4bn
Q1 202115 holders, $3.6bn31 holders, $15.4bn
Q2 202116 holders, $4.9bn30 holders, $12.7bn
Q3 202121 holders, $5.9bn35 holders, $10.1bn
Q4 202118 holders, $6.8bn28 holders, $12.4bn
Q1 202220 holders, $6.3bn23 holders, $16.1bn
Q2 202219 holders, $4.4bn25 holders, $18.1bn
Q3 202223 holders, $2.9bn22 holders, $18.4bn
Q4 202220 holders, $2.2bn28 holders, $18.4bn
Q1 202319 holders, $3.9bn26 holders, $21.4bn
Q2 202319 holders, $4.1bn27 holders, $24.7bn
Q3 202320 holders, $4.3bn33 holders, $24.3bn
Q4 202316 holders, $3.5bn32 holders, $28.6bn
Q1 202417 holders, $4.1bn31 holders, $29.8bn
Q2 202414 holders, $3.2bn29 holders, $33.4bn
Q3 202414 holders, $2.9bn27 holders, $33.5bn
Q4 202417 holders, $3.0bn26 holders, $28.5bn
Q1 202512 holders, $1.4bn21 holders, $35.4bn
Q2 202513 holders, $1.3bn21 holders, $32.3bn
Q3 202513 holders, $2.1bn22 holders, $25.9bn
Q4 202516 holders, $1.6bn26 holders, $31.8bn
Q1 202612 holders, $1.3bn25 holders, $31.8bn
Q2 202612 holders, $3.1bn26 holders, $34.6bn
WST

West Pharmaceutical SVSC Inc

Holders
16
Reported value
$1.6bn
Buyers
25
Sellers
14

Breadth +11 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WST (12)

AQR Capital Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, ExodusPoint Capital Management LP, Holocene Advisors LP, Moore Capital Management LP, Point72 Asset Management LP, Quantbot Technologies LP, Steadfast Capital Management LP, Two Sigma Investments LP, Viking Global Investors LP, Walleye Capital LLC

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →